With decades of leadership experience in the life science industry, our team fosters an ethos of innovation to develop regenerative medicine therapies aimed at treating a range of serious liver diseases. 

Mr. Crouch has been our CEO and President since 2017 and has over 25 years of experience building and leading technology, expertise and product-based companies in the life sciences and biotech industries. Prior to Organovo, he managed and served as an operational investor in a group of leading clinical research site companies.  Specifically, Mr. Crouch served as Chief Executive Officer at eStudySite, a position he held from January 2009 to June 2016; as Executive Chairman of Meridien Research from December 2013 to September 2016; and as a Director of the National Research Institute from September 2011 through July 2016.  He was instrumental in building these three sister companies, and helping them to achieve significant and profitable growth and to become recognized leaders in their respective fields of infectious disease, CNS disorders and metabolic disease.  Prior to this, Mr. Crouch served as Senior Vice President of Operations/President International at Ligand Pharmaceuticals (NASDAQ: LGND) from 2005 to 2007, with responsibilities for new business development, technical operations, international sales and clinical research.  Prior to Ligand, he was President and Chief Operating Officer of Discovery Partners International (NASDAQ: formerly DPII – a large drug discovery services and technology provider).  Earlier in his career, he was Chief Executive Officer of Variagenics (NASDAQ: formerly VGNX – a leading pharmacogenomics company), Senior Vice President of Marketing and Sales at Parexel (NASDAQ: formerly PRXL) – a global CRO, and he also held international management positions in new product development and commercialization at Pfizer and Schering Plough.  Mr. Crouch serves on the Board of Directors of BIOCOM, an organization comprising 1,100 life sciences companies throughout California.  Mr. Crouch holds a BSE in chemical engineering, cum laude, from Princeton University and an MBA in international marketing and finance from the University of Chicago.

Mr. Kussman has more than 30 years of financial and general management experience in the healthcare and technology sectors.  He is an accomplished executive with extensive financial, strategic and operational experience in biotechnology and technology companies ranging from large public multinational corporations to private start-ups.  Mr. Kussman spent the prior 2 years at ALPHAEON® Corporation as CFO, where he helped raise over $150 million in equity and debt capital, as well as complete five acquisitions to help the company scale rapidly.  Prior to this role, Mr. Kussman served as CFO at XIFIN, Inc., where he helped lead XIFIN’s private equity recapitalization with GTCR.  In addition, Mr. Kussman served as CFO and co-CEO at Breach Security, before successfully negotiating its sale to Trustwave, and as CFO and senior vice president of corporate development for Ascenta Therapeutics, a development stage biopharmaceutical company, leading the company’s $52 million Series C financing.  Kussman has also held senior executive positions at Discovery Partners International, Inc., SYNAVANT Inc., Cognizant Corp., and IMS Health, in addition to various financial and corporate development positions at The Dun Bradstreet Corporation.  Kussman earned a B.A. cum laude in economics and mathematics from Pomona College and an M.B.A. with distinction in Finance from the Wharton School of Business at the University of Pennsylvania.

Ms. Bush has nearly 20 years of legal, regulatory, government relations and general management experience. Prior to joining Organovo, Ms. Bush held positions of increasing responsibility at Broadcom Corp., where she was most recently Associate General Counsel. Before joining Broadcom, Ms. Bush served as Associate General Counsel of DivX, Inc. until its acquisition by Sonic Solutions in October 2010. Earlier in her career, Ms. Bush was a Principal at Fish Richardson, from 2001 to January 2010, where she represented clients focused on a variety of technologies, including in the areas of medical devices, life sciences, software and consumer products. Ms. Bush received a J.D. from Yale Law School and an A.B. in history and Latin American Studies from Princeton University.